Unlocking the Therapeutic Potential of the Tumor Microenvironment (TME)

Gaining a better understanding of how tumors interact with their microenvironment will allow improved patient response in the clinic and reduce attrition for novel oncology drugs. Unlocking a whole host of novel targets for drug discovery, it could also provide the power to overcome acquired resistance to front line therapies.

Following on from the success of  “Targeting the Tumor Microenvironment” Target TME is a unique meeting that brings together academic leaders and prominent researchers throughout industry to push TME research forwards into effective drug discovery.

Designed in collaboration with Michael Lisanti, founder of “The Autophagic Tumor Stroma Model of Cancer Metabolism” and Suresh Mohla, Chief & Division Associate Director, Tumor Biology and Metastasis Branch, NCI. Target TME will deliver an unparalleled speaker line up and a powerful mix of attendees from industry and academia.